Nvest Financial LLC Invests $2.24 Million in GSK PLC Sponsored ADR $GSK

Nvest Financial LLC acquired a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 42,661 shares of the pharmaceutical company’s stock, valued at approximately $2,236,000.

A number of other hedge funds also recently made changes to their positions in GSK. Fisher Asset Management LLC increased its holdings in GSK by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock worth $1,627,931,000 after acquiring an additional 968,370 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in GSK by 2,032.8% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock valued at $41,896,000 after purchasing an additional 814,275 shares in the last quarter. Kahn Brothers Group Inc. purchased a new position in GSK during the second quarter valued at approximately $8,305,000. Align Financial LLC bought a new position in shares of GSK in the fourth quarter worth approximately $5,628,000. Finally, Leuthold Group LLC bought a new position in shares of GSK in the fourth quarter worth approximately $4,922,000. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Morgan Stanley reissued an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Jefferies Financial Group upgraded shares of GSK to a “strong-buy” rating in a research note on Friday, July 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a report on Thursday, July 30th. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Citigroup started coverage on GSK in a research report on Friday, July 24th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $53.00.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to license exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to Hutchmed’s experimental KRAS-EGFR antibody-drug conjugate, HMPL-A830. The deal includes a reported $110 million upfront payment and could be worth up to $1.295 billion in total milestone payments, giving GSK access to a potentially differentiated solid-tumor treatment. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: Deutsche Bank said GSK’s Phase II mRNA flu vaccine results closely track data from Moderna’s comparable candidate. The read-through supports the credibility of GSK’s vaccine platform and could strengthen expectations for a future product in the seasonal influenza market. GSK’s mRNA flu vaccine data closely tracks Moderna’s
• Neutral Sentiment: Coverage also points to solid first-half growth and continued support from the licensing transaction. However, HMPL-A830 is an experimental, early-stage asset, so GSK must fund further development and still faces clinical, regulatory and commercial execution risks before the program can generate revenue. GSK stock gains support from licensing deal and solid first-half growth

GSK Trading Down 1.9%

Shares of GSK opened at $49.88 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. GSK PLC Sponsored ADR has a 1 year low of $39.29 and a 1 year high of $61.69. The company has a 50 day simple moving average of $51.70 and a two-hundred day simple moving average of $53.20. The firm has a market cap of $100.89 billion, a P/E ratio of 15.60, a price-to-earnings-growth ratio of 1.95 and a beta of 0.35.

GSK (NYSE:GSK) last released its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.02 billion. During the same quarter in the previous year, the firm earned $0.47 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts expect that GSK PLC Sponsored ADR will post 4.83 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be paid a $0.4515 dividend. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date is Friday, August 14th. This is an increase from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio is presently 55.63%.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.